131I treatment of thyroid papillary carcinoma in a patient with renal failure
- 15 December 1990
- Vol. 66 (12) , 2509-2513
- https://doi.org/10.1002/1097-0142(19901215)66:12<2509::aid-cncr2820661211>3.0.co;2-m
Abstract
Procedures for 131I ablation in renal failure are not known. in one patient receiving dialysis, detailed dosimetry and health safety aspects were obtained. the results showed insignificant contamination of equipment, but a surprisingly significant reduction in biologic half‐life of 131I due to efficient dialysis extraction. the data indicate that 131I ablation can be done safely and easily during dialysis but that much higher 131I doses must be used to achieve equivalent results to those obtained in patients with normal renal function.This publication has 11 references indexed in Scilit:
- Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinomaRadiotherapy and Oncology, 1989
- Radioiodine therapy of thyroid diseaseInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1987
- Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid CancerNew England Journal of Medicine, 1983
- Iodine 131 ablation therapy for a patient on maintenance haemodialysisThe British Journal of Radiology, 1981
- A comparison of methods for assessing patient body burden following 131I therapy for thyroid cancer.Radiology, 1980
- Treatment of diffuse toxic goiter with 131ISeminars in Nuclear Medicine, 1971
- Radioiodine dosimetry and the use of radioiodines other than 131I in thyroid diagnosisSeminars in Nuclear Medicine, 1971
- Kinetic Analysis of Iodine Metabolism1Journal of Clinical Endocrinology & Metabolism, 1966
- An Autoregulatory Effect of Iodide in Diverse Thyroid DisordersAnnals of Internal Medicine, 1965